Organversagen Gerinnung: Diagnostik, Management und therapeutische Konsequenzen

disseminierte intravasale Gerinnung - Blutung - Leberversagen

disseminated intravascular coagulation - bleeding - liver failure

Literatur

• 1 Bernard G R, Vincent J L, Laterre P F, LaRosa S P, Dhainaut J F, Lopez-Rodriguez A, Steingrub J S. et al . Efficacy and safety of recombinant human activated protein C for severe sepsis.  N Engl J Med. 2001;  344 699-709
• 2 Blauhut B, Kramar H, Vinazzer H, Bergmann H. Substitution of antithrombin III in shock and DIC.  Thromb Res. 1985;  39 81-89
• 3 Dhainaut J F, Yan S B, Margolis B D, Lorente J A, Russell J A, Freebairn R C, Spapen H D. et al . Drotrecogin alfa (activated) (recombinant human activated protein C) reduces host coagulopathy response in patients with severe sepsis.  Thromb Haemost. 2003;  90 642-653
• 4 Fourrier F, Chopin C, Huart J J, Runge I, Caron C, Goudemand J. Double-blind, placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation.  Chest. 1993;  104 882-888
• 5 Gando S, Iba T, Eguchi Y, Ohtomo Y, Okamoto K. et al . A multicenter, prospective validation of disseminated intravascular coagulation diagnostic criteria for critically ill patients.  Crit Care Med. 2006;  34 625-631
• 6 Hoffmann J N, Vollmar B, Laschke M W, Inthorn D, Kaneider N C, Dunzendorfer S, Wiedermann C J. et al . Adverse effect of heparin on antithrombin action during endotoxemia: microhemodynamic and cellular mechanisms.  Thromb Haemost. 2002;  88 242-252
• 7 Hoffmann J N, Wiedermann C J, Juers M, Ostermann H, Kienast J, Briegel J, Strauss R. et al . Benefit/risk profile of high-dose antithrombin in patients with severe sepsis treated with and without concomitant heparin.  Thromb Haemost. 2006;  95 850-856
• 8 Kienast J, Juers M, Wiedermann C J, Hoffmann J N, Ostermann H, Strauss R. et al . Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation.  J Thromb Haemost. 2006;  4 90-97
• 9 Levi M, Peters M, Buller H R. Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding.  Crit Care Med. 2005;  33 883-890
• 10 Minnema M C, Chang A C, Jansen P M, Lubbers Y T, Pratt B M, Whittaker B G, Taylor F B. et al . Recombinant human antithrombin III improves survival and attenuates inflammatory responses in baboons lethally challenged with Escherichia coli.  Blood. 2000;  95 1117-1123
• 11 O’Connell K A, Wood J J, Wise R P, Lozier J N, Braun M M. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa.  JAMA. 2006;  295 293-298
• 12 Taylor jr. F B, Toh C H, Hoots W K, Wada H, Levi M. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation.  Thromb Haemost. 2001;  86 1327-1330
• 13 Warren B L, Eid A, Singer P, Pillay S S, Carl P, Novak I, Chalupa P. et al . Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial.  JAMA. 2001;  286 1869-1878